CBAS Heparin Coating

The Carmeda BioActive Surface (CBAS™) is the product of Carmeda AB in Stockholm, Sweden. Carmeda has an extensive bibliography of CBAS™ applications, particularly in human-use devices. CBAS™ applications in humans include central venous catheters, coronary stents, ventricular assist devices, extracorporeal blood circuits, blood sampling devices, and vascular grafts. CBAS™ is used to coat devices from J&J, Medtronic, and Gore. In lab animal research, CBAS™-coated catheters are used for arterial and venous access. Also, CBAS™ provides dramatic improvement in catheter patency for chronic lymphatic access.

Rat Data - Published in Comparative Medicine (June 2002)

Request a copy

Catheter Type Median Patency Culture-Positive* Uncoated 17.5 days 3 of 8 CBAS™ coated 30 days (study end) 0 of 9 * Blood culture positive for Staphylococcus intermedius or S. aureus

How It Works

CBAS™ is a patented process for applying heparin to the surfaces of biomaterials. Unlike TDMAC heparin, the CBAS™ covalent bonds last several months. The "active sequence" of the heparin molecule serves to halt the clotting cascade. The endothelial lining of blood vessels contains a heparin-like substance which performs like CBAS™. The novel aspect of CBAS™ is that the active sequence remains available over and over to bind with antithrombin. No other coating can achieve this long-term function.

CBAS™ is the most respected thromboresistant coating available in the human-use medical device industry. It is under license to Solomon Scientific for use in laboratory animal research applications. Unlike hydrogels, CBAS™ is bioactive, not passive. It has been proven repeatedly to minimize the thrombogenecity of intravascular devices.

Long-Term, Non-Leaching

CBAS™ is not consumed. The heparin "active sequence" repeatedly binds to antithrombin to prevent clotting. As such, half-life is not an issue. CBAS™ is "end-point attached" to the catheter surface and does not elute into the bloodstream.

  1. CBAS™ heparin "active sequence" is available to bind with antithrombin.

  2. Antithrombin conforms to accelerate binding with thrombin and other coagulation factors.

  3. Coagulation effect of thrombin is neutralized by formation of thrombin-antithrombin complex.

  4. Thrombin-antithrombin complex washes away. CBAS™ heparin "active sequence" remains intact and is available repeatedly to bind with antithrombin.

Reduces Infection

Human clinical studies using CBAS™ and other heparin coatings document a clear anti-infective benefit from heparin coatings. While heparin is not an antimicrobial per se, it does remove the blood nidus for microorganisms thereby minimizing the nutrients and binding sites for many of the unfavorable blood proteins. Appelgren et al demonstrated a 50% reduction in infections from CBAS™ coated catheters in humans. Visit www.carmeda.com for additional information and complete CBAS™ bibliography (200+ references).

Applications

• Venous access
• Arterial access
• Blood collection circuits
• Lymphatic access

U.S. Pricing

Download

catheters information [PDF]